Which Big Name Protease Inhibitor Left the Hepatitis C Market?
Share
Follow Us
The Editors at Hepatitis Central
June 25, 2014
Find out why Germany’s Boehringer Ingelheim has stopped development of faldepravir, its lead candidate in the HCV market.
Boehringer pulls faldepravir and exits hepatitis C market
Unable to challenge all-oral options from Gilead and others
Germany’s Boehringer Ingelheim is bowing out of the race to develop oral hepatitis C virus (HCV) therapies and has discontinued development of lead candidate faldepravir.
After a strategic review of its business, the company said it had elected to withdraw all regulatory filings for faldepravir – a protease inhibitor – because the “HCV treatment environment has significantly and rapidly evolved” in the last couple of years.
Continue reading this entire article:
http://www.pmlive.com/pharma_news/boehringer_pulls_faldepravir_and_exits_hcv_market_580066
